A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
Public ClinicalTrials.gov record NCT06496178. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared With Investigator's Choice Monotherapy Treatment in Previously Treated Patients With Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Study identification
- NCT ID
- NCT06496178
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 621 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 24, 2024
- Primary completion
- Jan 31, 2028
- Completion
- Feb 28, 2029
- Last update posted
- Aug 30, 2026
2024 – 2029
United States locations
- U.S. sites
- 62
- U.S. states
- 30
- U.S. cities
- 55
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 160 | Mobile | Alabama | 36608 | — |
| Site 102 | Prescott | Arizona | 86301 | — |
| Site 125 | Scottsdale | Arizona | 85054 | — |
| Site 82 | Duarte | California | 91010 | — |
| Site 25 | La Jolla | California | 92037 | — |
| Site 173 | Orange | California | 92868 | — |
| Site 28 | Palo Alto | California | 94304 | — |
| Site 127 | Sacramento | California | 95817 | — |
| Site 46 | San Francisco | California | 94158 | — |
| Site 130 | Lone Tree | Colorado | 80124 | — |
| Site 104 | Washington D.C. | District of Columbia | 20010 | — |
| Site 12 | Fort Myers | Florida | 33901 | — |
| Site 123 | Jacksonville | Florida | 32224 | — |
| Site 9 | Orlando | Florida | 32827 | — |
| Site 138 | Tampa | Florida | 33612 | — |
| Site 187 | Atlanta | Georgia | 30322 | — |
| Site 207 | Atlanta | Georgia | 30341 | — |
| Site 152 | Chicago | Illinois | 60607 | — |
| Site 213 | Chicago | Illinois | 60611 | — |
| Site 68 | Chicago | Illinois | 60637 | — |
| Site 31 | Indianapolis | Indiana | 46202 | — |
| Site 8 | Louisville | Kentucky | 40202 | — |
| Site 40 | Baton Rouge | Louisiana | 70809 | — |
| Site 100 | New Orleans | Louisiana | 70121 | — |
| Site 153 | Columbia | Maryland | 21044 | — |
| Site 77 | Boston | Massachusetts | 02215 | — |
| Site 103 | Ann Arbor | Michigan | 48109 | — |
| Site 5 | Detroit | Michigan | 48201 | — |
| Site 49 | Maple Grove | Minnesota | 55369 | — |
| Site 124 | Rochester | Minnesota | 55905 | — |
| Site 18 | St Louis | Missouri | 63110 | — |
| Site 86 | Hackensack | New Jersey | 07601 | — |
| Site 15 | Albuquerque | New Mexico | 87131 | — |
| Site 24 | New York | New York | 10029 | — |
| Site 214 | The Bronx | New York | 10461 | — |
| Site 98 | Chapel Hill | North Carolina | 27514 | — |
| Site 122 | Durham | North Carolina | 27710 | — |
| Site 23 | Cincinnati | Ohio | 45219 | — |
| Site 218 | Cleveland | Ohio | 44106 | — |
| Site 87 | Cleveland | Ohio | 44195 | — |
| Site 32 | Columbus | Ohio | 43210 | — |
| Site 26 | Portland | Oregon | 97213 | — |
| Site 151 | Bensalem | Pennsylvania | 19020 | — |
| Site 158 | Philadelphia | Pennsylvania | 19107 | — |
| Site 159 | Philadelphia | Pennsylvania | 19114 | — |
| Site 50 | Charleston | South Carolina | 29425 | — |
| Site 60 | Chattanooga | Tennessee | 37404 | — |
| Site 54 | Memphis | Tennessee | 38103 | — |
| Site 59 | Nashville | Tennessee | 37203 | — |
| Site 67 | Nashville | Tennessee | 37232 | — |
| Site 55 | Denison | Texas | 75020 | — |
| Site 34 | El Paso | Texas | 79915 | — |
| Site 51 | Houston | Texas | 77030 | — |
| Site 7 | Houston | Texas | 77030 | — |
| Site 94 | Pearland | Texas | 77584 | — |
| Site 4 | Salt Lake City | Utah | 84112 | — |
| Site 10 | Blacksburg | Virginia | 24060 | — |
| Site 22 | Charlottesville | Virginia | 22908 | — |
| Site 156 | Winchester | Virginia | 22601 | — |
| Site 163 | Seattle | Washington | 98109 | — |
| Site 6 | Spokane | Washington | 99202 | — |
| Site 216 | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 146 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06496178, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 30, 2026 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06496178 live on ClinicalTrials.gov.